Laurus Labs | CMP: Rs 444.65 | The share price was down over 15 percent as the company continues to grapple with high industry-wide channel inventory, slower demand and pricing pressure in antiretroviral (ARV) formulations and active pharmaceutical ingredients (APIs), said analysts, as they cut the firm's earnings estimates for FY23 and FY24 by 7-11 percent, according to media reports. Motilal Oswal has cut its EPS estimates by 8 per cent for FY23 and 9 per cent for FY24 to factor in a steep price erosion in ARV products, lesser tender wins in ARV formulation, and increased overall operational cost.

Moneycontrol Pro Panorama | SEBI gets sharper teeth
Dec 22, 2025 / 02:31 PM IST
For Moneycontrol's Pro Panorama December 22 edition: Indian markets likely to witness a year-end rally ahead, India's trade deal b...
Read NowAre you a PRO subscriber? Sign In
Ad free Experience
Seamless navigation, faster responses.
Expert Perspective
Explore 230+ exclusive editorials every month
+
Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights
40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events
Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters
Stay ahead with daily and weekly insights
Unlock exclusive discounts